This review discusses the evidence in support of the use of sunitinib malate (Sutent®) in the treatment of metastatic renal cell carcinoma (mRCC).
Commentary has been provided by Dr Rohit Joshi, Medical Oncology Consultant at the Lyell McEwin Hospital and Calvary Central Districts Hospital in Adelaide.
Please login below to download this issue (PDF)